CBIO logo

CBIO
Crescent Biopharma Inc.

6,064
Mkt Cap
$569.36M
Volume
419,767.00
52W High
$27.41
52W Low
$8.72
PE Ratio
-1.65
CBIO Fundamentals
Price
$20.65
Prev Close
$21.47
Open
$21.40
50D MA
$19.05
Beta
0.59
Avg. Volume
268,692.50
EPS (Annual)
-$14.78
P/B
3.17
Rev/Employee
$246,454.55
$84.04
Loading...
Loading...
News
all
press releases
HC Wainwright Issues Pessimistic Outlook for CBIO Earnings
Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Crescent Biopharma in a note issued to investors on Monday, May 4th. HC Wainwright analyst M. Kapoor now forecasts that the biopharmaceutic...
MarketBeat
News Placeholder
More News
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3% - Here's Why
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 8.3% - Here's Why...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell?
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts
Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened
Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - What's Next...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving Average - Time to Sell?
Crescent Biopharma (NASDAQ:CBIO) Share Price Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages
Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three h...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat
News Placeholder
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright
HC Wainwright decreased their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday...
MarketBeat
News Placeholder
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are covering the company, Marketbeat.com...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available